FGP
AKTS

Freestone Grove Partners’s Aktis Oncology AKTS Stock Holding History

Freestone Grove Partners’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64 Buy
+2
New +$41 ﹤0.01% 936

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Freestone Grove Partners's AKTS Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Aktis Oncology (AKTS) in Q2 2026: 2 shares worth $64. The stake represents ﹤0.01% of the portfolio and ranks #936 among its holdings.

114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Freestone Grove Partners held 2 shares of Aktis Oncology worth $64 as of Q2 2026.
  • Aktis Oncology was a new Freestone Grove Partners position in Q2 2026.
  • Aktis Oncology made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #936 holding.
  • 114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.